Albany Molecular Research (AMRI) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-54.76M
Depreciation and amortization	31.29M
Deferred income taxes
Impairment and loss on disposal of property, plant and equipment
Stock-based compensation expense	6.42M
Recoveries of bad debt
Write down for obsolete inventories
Accounts receivable	14.13M
Royalty income receivable	2.18M
Inventory, prepaid expenses and other assets
Income taxes receivable
Accounts payable and accrued expenses	-2.54M
Deferred revenue and licensing fees	-3.85M
Pension and postretirement benefits	-107K
Other long-term liabilities
Net cash (used in) provided by operating activities
Purchases of investment securities
Proceeds from sales and maturities of investment securities
Purchase of business, net of cash acquired	-144.33M
Purchase of property, plant and equipment	-37.95M
Payments for patent applications and other costs	-188K
Net cash provided by (used in) investing activities
Principal payments on long-term debt	-44.88M
Purchase of treasury stock	-842K
Proceeds from sale of common stock	1.83M
Tax benefit of stock based compensation
Net cash used in financing activities
Effect of exchange rate changes on cash flows	-48K
Decrease in cash and cash equivalents	-4.59M
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period

Entities mentioned with AMRI

View All Entities